See more : Thiensurat Public Company Limited (TSR.BK) Income Statement Analysis – Financial Results
Complete financial analysis of BioPorto A/S (THOXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPorto A/S, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Greenbrook TMS Inc. (GTMS.TO) Income Statement Analysis – Financial Results
- Jindal Worldwide Limited (JINDWORLD.NS) Income Statement Analysis – Financial Results
- Imperial Brands PLC (ITB.DE) Income Statement Analysis – Financial Results
- Witted Megacorp Oyj (WITTED.HE) Income Statement Analysis – Financial Results
- RLJ Lodging Trust (RLJ) Income Statement Analysis – Financial Results
BioPorto A/S (THOXF)
About BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.96M | 28.97M | 24.25M | 23.20M | 26.62M | 26.02M | 25.16M | 20.72M | 20.38M | 18.71M | 16.63M | 17.86M | 18.58M | 13.80M | 11.01M | 8.34M | 8.34M | 5.55M | 4.36M |
| Cost of Revenue | 10.78M | 9.93M | 9.21M | 9.87M | 9.29M | 8.18M | 6.91M | 5.03M | 4.90M | 5.51M | 7.58M | 6.80M | 8.06M | 5.34M | 4.75M | 4.62M | 4.62M | 2.42M | 4.49M |
| Gross Profit | 20.18M | 19.04M | 15.04M | 13.34M | 17.33M | 17.84M | 18.25M | 15.69M | 15.48M | 13.20M | 9.04M | 11.06M | 10.52M | 8.46M | 6.26M | 3.72M | 3.72M | 3.13M | -123.00K |
| Gross Profit Ratio | 65.19% | 65.73% | 62.01% | 57.49% | 65.09% | 68.55% | 72.54% | 75.74% | 75.95% | 70.55% | 54.39% | 61.91% | 56.61% | 61.28% | 56.85% | 44.58% | 44.58% | 56.43% | -2.82% |
| Research & Development | 25.45M | 34.94M | 30.26M | 28.13M | 24.56M | 18.68M | 21.93M | 9.67M | 9.94M | 8.62M | 10.21M | 9.91M | 8.13M | 8.90M | 8.64M | 6.38M | 6.38M | 7.64M | 6.68M |
| General & Administrative | 36.03M | 41.83M | 32.66M | 28.02M | 27.80M | 20.01M | 14.27M | 13.03M | 9.42M | 10.44M | 12.67M | 9.04M | 8.79M | 8.26M | 7.97M | 7.48M | 7.48M | 7.89M | 5.32M |
| Selling & Marketing | 18.87M | 21.22M | 17.38M | 20.79M | 39.27M | 20.94M | 18.55M | 18.04M | 8.88M | 9.40M | 5.97M | 5.97M | 6.46M | 4.71M | 5.67M | 3.90M | 3.90M | 2.26M | 2.23M |
| SG&A | 54.90M | 63.05M | 50.04M | 48.80M | 67.07M | 40.94M | 32.81M | 31.07M | 18.30M | 19.84M | 18.63M | 15.01M | 15.25M | 12.97M | 13.63M | 11.38M | 11.38M | 10.15M | 7.55M |
| Other Expenses | 1.01M | 274.00K | -548.00K | -474.00K | -591.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.35M | 97.99M | 80.30M | 76.93M | 91.63M | 59.62M | 54.74M | 40.74M | 28.24M | 28.45M | 28.85M | 24.92M | 23.38M | 21.87M | 22.28M | 17.76M | 16.78M | -11.53M | -14.48M |
| Cost & Expenses | 92.13M | 107.91M | 89.51M | 86.79M | 100.92M | 67.80M | 61.65M | 45.77M | 33.14M | 33.96M | 36.43M | 31.73M | 31.44M | 27.21M | 27.03M | 22.39M | 21.40M | -9.11M | -9.99M |
| Interest Income | 1.04M | 44.00K | 0.00 | 4.00K | 75.00K | 27.00K | 25.00K | 64.00K | 93.00K | 210.00K | 56.00K | -273.00K | 68.00K | 93.00K | 124.00K | 1.75M | 763.00K | 1.26M | 755.00K |
| Interest Expense | 571.00K | 1.09M | 912.00K | 780.00K | 326.00K | 38.00K | 31.00K | 29.00K | 279.00K | 15.00K | 1.68M | 1.82M | 2.05M | 889.00K | 61.00K | 125.00K | 982.00K | 190.00K | 153.00K |
| Depreciation & Amortization | 2.68M | 3.97M | 4.33M | 3.99M | 2.86M | 543.00K | 504.00K | 390.00K | 300.00K | 270.00K | 107.00K | 189.00K | 8.00K | 325.00K | 345.00K | 384.00K | 395.00K | 442.00K | 460.00K |
| EBITDA | -57.96M | -77.81M | -58.60M | -62.06M | -71.06M | -41.04M | -36.53M | -24.48M | -12.44M | -14.81M | -20.09M | -13.94M | -12.88M | -12.99M | -15.55M | -14.23M | -12.67M | -12.96M | 15.57M |
| EBITDA Ratio | -187.21% | -255.13% | -241.61% | -267.45% | -266.94% | -157.73% | -145.22% | -118.15% | -61.01% | -79.18% | -120.85% | -78.08% | -68.78% | -94.14% | -141.24% | -163.80% | -151.89% | 294.54% | 356.95% |
| Operating Income | -61.17M | -77.88M | -65.26M | -63.59M | -74.30M | -41.78M | -36.49M | -25.05M | -12.76M | -15.26M | -19.80M | -13.87M | -12.86M | -13.41M | -16.02M | -14.05M | -14.05M | 14.66M | 14.36M |
| Operating Income Ratio | -197.60% | -268.83% | -269.05% | -274.05% | -279.09% | -160.60% | -145.08% | -120.88% | -62.60% | -81.56% | -119.11% | -77.67% | -69.19% | -97.17% | -145.50% | -168.41% | -168.41% | 263.94% | 329.09% |
| Total Other Income/Expenses | -35.00K | -2.60M | 1.42M | -3.24M | 52.00K | 164.00K | -570.00K | 148.00K | -255.00K | 159.00K | -2.07M | -2.08M | -1.98M | -796.00K | 63.00K | -697.00K | -219.00K | 30.39M | 602.00K |
| Income Before Tax | -61.21M | -81.55M | -63.84M | -66.83M | -74.25M | -41.62M | -37.06M | -24.90M | -13.01M | -15.10M | -21.87M | -15.95M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | 15.73M | 14.96M |
| Income Before Tax Ratio | -197.71% | -281.50% | -263.21% | -288.03% | -278.89% | -159.97% | -147.34% | -120.17% | -63.85% | -80.71% | -131.57% | -89.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | 283.17% | 342.89% |
| Income Tax Expense | -4.88M | -5.62M | -6.73M | -5.27M | -4.61M | -3.57M | -4.82M | -2.10M | -2.28M | -2.17M | -1.25M | -1.25M | 68.00K | 93.00K | 124.00K | 0.00 | 982.00K | 32.71M | 30.67M |
| Net Income | -56.33M | -75.92M | -57.11M | -61.56M | -69.64M | -38.05M | -32.24M | -22.80M | -10.73M | -12.93M | -20.62M | -14.70M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | -15.73M | -14.96M |
| Net Income Ratio | -181.95% | -262.08% | -235.48% | -265.31% | -261.60% | -146.25% | -128.18% | -110.04% | -52.65% | -69.10% | -124.05% | -82.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | -283.17% | -342.89% |
| EPS | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| EPS Diluted | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| Weighted Avg Shares Out | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
| Weighted Avg Shares Out (Dil) | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
BioPorto CEO Peter Mørch Erikse set to step aside
BioPorto A/S (CPH:BIOPOR) (FRA:2P4) announced that its chief executive officer of nearly eight years, Peter Mørch Eriksen, will resign his position with the company once his successor has been found. Mørch Eriksen, however, will continue to support the company until the end of January 2022.
Peter Mørch Eriksen resigns as CEO of BioPorto A/S
May 5 , 20 2 1 Announcement no. 10
BioPorto launches search for new CFO following Ole Larsen's resignation
BioPorto A/S (CPH:BIOPOR) (FRA:2P4) announced that it has begun a search for a new CFO after Ole Larsen resigned to pursue opportunities outside the company. Larsen had served as CFO and a member of the company's management team since 2018.
BioPorto initiates search for new CFO as Ole Larsen resigns
April 2 6 , 20 2 1 Announcement no . 8
BioPorto says 2021 "will be a pivotal year" as it publishes its 2020 Annual Report
BioPorto A/S (CPH:BIOPOR) has published its 2020 Annual Report in which it said 2021 "will be a pivotal year". The Danish in-vitro diagnostics company's CEO Peter Mørch Eriksen said in the report: “While 2020 on all accounts was a difficult year, I...
BioPorto Announces the 2020 Annual Report
March 17, 2021
Source: https://incomestatements.info
Category: Stock Reports